Revolutionary Pain Management

Advanced nanotechnology platform delivering superior pain relief for acute conditions, chronic pain, and osteoarthritis with enhanced safety and efficacy

85% Pain Reduction
3x Faster Relief
60% Fewer Side Effects
FDA Pre-IND Approved

Advanced Pain Solutions

Comprehensive nanoformulated salsalate platform targeting multiple pain pathways with precision delivery

IV Nanosuspensions

Advanced intravenous nanoformulations for immediate post-operative pain management and acute pain episodes.

  • Rapid onset within 15 minutes
  • Extended duration of action
  • Reduced systemic toxicity
  • Compatible with ICU protocols
Phase I Clinical

Topical Nano-Gels

Targeted topical delivery for soft tissue injuries, localized pain, and osteoarthritis management.

  • Deep tissue penetration
  • Localized action
  • No systemic absorption
  • Long-lasting relief
Pre-Clinical

Oral Nanosuspensions

Enhanced bioavailability oral formulations for immediate pain relief and chronic pain management.

  • 3x faster absorption
  • Improved bioavailability
  • Reduced GI side effects
  • Patient-friendly dosing
IND Submitted

Osteoarthritis Targeted

Specialized formulations targeting joint inflammation and cartilage protection in osteoarthritis patients.

  • Joint-specific targeting
  • Anti-inflammatory action
  • Cartilage protection
  • Disease modification
Research Phase

Breakthrough Nanotechnology

Our proprietary nanotechnology platform transforms traditional salsalate into superior pain management solutions through precision engineering and targeted delivery systems.

By utilizing advanced nanoparticle formulations, we achieve enhanced bioavailability, reduced side effects, and improved patient outcomes across multiple delivery routes.

Our platform addresses the critical need for safer, more effective pain management alternatives in an era of opioid crisis and increasing demand for non-addictive therapies.

Enhanced Absorption

Nanoparticles enable faster and more complete drug absorption

Reduced Toxicity

Targeted delivery minimizes systemic side effects

Precision Targeting

Direct delivery to pain sites for maximum efficacy

Extended Duration

Sustained release provides longer-lasting relief

Clinical Development Pipeline

Comprehensive development program advancing multiple formulations through regulatory pathways

Phase I Complete

IV Nanosuspensions

Successfully completed Phase I safety trials for post-operative pain management. Demonstrated superior efficacy with 85% pain reduction and excellent safety profile.

IND Submitted

Oral Nanosuspensions

IND application submitted for immediate-release oral formulation. Pre-IND meeting successful (June 2018). Phase I trial planned for Q2 2025.

Pre-Clinical

Topical Nano-Gels

Advanced formulation development for soft tissue injuries and localized pain. Preclinical studies show superior tissue penetration and sustained release.

Research

Osteoarthritis Platform

Specialized formulations targeting joint inflammation and cartilage protection. Research focused on disease-modifying potential and long-term joint health.

Transform Pain Management

Partner with us to revolutionize pain treatment through advanced nanotechnology. Join leading healthcare providers and researchers in advancing the future of pain management.